Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1382-1392
Open Access | Times Cited: 405

Showing 1-25 of 405 citing articles:

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Markus Hoffmann, Nadine Krüger, Sebastian Schulz, et al.
Cell (2021) Vol. 185, Iss. 3, pp. 447-456.e11
Open Access | Times Cited: 869
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
Hongchao Pan, Richárd Pető, Ana María Henao-Restrepo, et al.
The Lancet (2022) Vol. 399, Iss. 10339, pp. 1941-1953
Open Access | Times Cited: 332
Antibodies to watch in 2022
Hélène Kaplon, Alicia M. Chenoweth, Silvia Crescioli, et al.
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 299
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 2, pp. 209-221
Open Access | Times Cited: 297
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 262
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
Hugh Montgomery, Richard Hobbs, Francisco Padilla, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 10, pp. 985-996
Open Access | Times Cited: 190
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Wesley H. Self, Uriel Sandkovsky, Cavan Reilly, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 5, pp. 622-635
Open Access | Times Cited: 182
Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series — 465 Health Care Facilities, United States, December 2020–October 2021
Christina Yek, Sarah Warner, Jennifer L. Wiltz, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 1, pp. 19-25
Open Access | Times Cited: 166
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
Rachel Yamin, Andrew Jones, Hans-Heinrich Hoffmann, et al.
Nature (2021) Vol. 599, Iss. 7885, pp. 465-470
Open Access | Times Cited: 162
The development of COVID-19 treatment
Yongliang Yuan, Baihai Jiao, Lili Qu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 150
COVID-19 therapeutics: Challenges and directions for the future
Philip C. Robinson, David Liew, Helen Tanner, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 15
Open Access | Times Cited: 142
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Antibodies to combat viral infections: development strategies and progress
Giuseppe Pantaleo, Bruno E. Correia, Craig Fenwick, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 676-696
Open Access | Times Cited: 138
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir
Ravi Shankar Prasad Singh, Sima S. Toussi, Frances Hackman, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 1, pp. 101-111
Open Access | Times Cited: 137
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
Takuya Tada, Hao Zhou, Belinda M. Dcosta, et al.
EBioMedicine (2022) Vol. 78, pp. 103944-103944
Open Access | Times Cited: 137
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 136
Potential therapeutic options for COVID-19: an update on current evidence
Zahra Niknam, Ameneh Jafari, Ali Golchin, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 136
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Nina Kreuzberger, Caroline Hirsch, Khai Li Chai, et al.
Cochrane library (2021) Vol. 2021, Iss. 9
Open Access | Times Cited: 134
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Zijun Wang, Frauke Muecksch, Alice Cho, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 998-1012.e8
Open Access | Times Cited: 128
Therapeutic advances in COVID-19
Naoka Murakami, Robert Hayden, Thomas Hills, et al.
Nature Reviews Nephrology (2022) Vol. 19, Iss. 1, pp. 38-52
Open Access | Times Cited: 128
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
Stephen J. Kent, David S. Khoury, Arnold Reynaldi, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 6, pp. 387-397
Open Access | Times Cited: 119
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 117
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 105
Two Years into the COVID-19 Pandemic: Lessons Learned
Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 9, pp. 1758-1814
Open Access | Times Cited: 103
Page 1 - Next Page

Scroll to top